- Home
- INM vs RDHL Comparison
INM vs RDHL Comparison
Compare INM & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- RDHL
- Stock Information
- Founded
- INM 1981
- RDHL 2009
- Country
- INM Canada
- RDHL Israel
- Employees
- INM N/A
- RDHL N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- INM Health Care
- RDHL Health Care
- Exchange
- INM Nasdaq
- RDHL Nasdaq
- Market Cap
- INM 4.3M
- RDHL 3.9M
- IPO Year
- INM N/A
- RDHL N/A
- Fundamental
- Price
- INM $2.36
- RDHL $1.70
- Analyst Decision
- INM
- RDHL
- Analyst Count
- INM 0
- RDHL 0
- Target Price
- INM N/A
- RDHL N/A
- AVG Volume (30 Days)
- INM 47.0K
- RDHL 43.1K
- Earning Date
- INM 11-13-2025
- RDHL 09-05-2025
- Dividend Yield
- INM N/A
- RDHL N/A
- EPS Growth
- INM N/A
- RDHL N/A
- EPS
- INM N/A
- RDHL N/A
- Revenue
- INM $4,920,990.00
- RDHL $9,550,000.00
- Revenue This Year
- INM N/A
- RDHL $381.91
- Revenue Next Year
- INM N/A
- RDHL N/A
- P/E Ratio
- INM N/A
- RDHL N/A
- Revenue Growth
- INM N/A
- RDHL 157.62
- 52 Week Low
- INM $1.72
- RDHL $1.06
- 52 Week High
- INM $8.27
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- INM 56.86
- RDHL 63.39
- Support Level
- INM $2.11
- RDHL $1.47
- Resistance Level
- INM $2.28
- RDHL $1.60
- Average True Range (ATR)
- INM 0.11
- RDHL 0.09
- MACD
- INM 0.03
- RDHL 0.04
- Stochastic Oscillator
- INM 78.57
- RDHL 97.98
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.